alexa Meser Ali | Cellular_and_Molecular_Imaging_Lab
ISSN: 2157-7439

Journal of Nanomedicine & Nanotechnology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Meser Ali

Meser Ali Meser M. Ali
Senior Staff Investigator
Director, Cellular and Molecular Imaging Lab
Department of Neurology
Henry Ford Hospital
Detroit, Michigan, USA

Meser M. Ali received his Ph.D. degree in Organometallic Chemistry from the University of Mie in Japan in 1999.  He is a Senior Staff Investigator in the Department of Neurology at Henry Ford Hospital, Detroit, Michigan, USA.   His research program focuses on the development of small-sized nanoparticles that can cross tumor blood brain barrier for potential applications of brain tumor imaging and therapy

Research Interest

My research interest is in the discipline of nanomedicine and drug delivery with noninvasive molecular imaging. Nanomedicine, carrying therapeutic payloads and delivered within close proximity of the tumor, can be designed to play a significant role in increasing treatment effectiveness while decreasing severity of side effects. Specifically, my research work focuses in developing small nano-sized paramagnetic nanoparticles that can cross tumor blood brain barrier and target primary glioblastoma multiform (GBM) selectively. My work resulted in the development of a series of new dendrimer-based multifunctional nanoparticles that are detected by standard MR relativity methods or new MRI methods based on Paramagnetic Chemical Exchange Saturation Transfer (PARACEST). My developments of small nano-sized molecular imaging agents that target GBM selectively. Therefore, primary GBM tumor selective drug delivery and imaging can be accomplished by using these dendrimer-based nanoparticles that possess long blood half-lives. We have reformulated promising anti-cancer drugs that failed to reach clinical trials, or failed in clinical trials due to toxicity or poor bioavailability. These reformulations have reproduced usable, safe therapies using nanoparticles. I have also used state-of-the-art MRI methods to study tumor progression and the early responses to chemotherapies in pre-clinical animal models.

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version